Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
UCB SA (EBR: UCB) bets $1.15 bn on Neurona Therapeutics to push epilepsy treatment beyond symptom control
Read More Technology Industry News Gamuda Berhad expands collaboration with Google Cloud to elevate gen AI capabilities across workforce In a significant move to boost its digital and innovative capabilities, Gamuda Berhad announced today its decision to… byPallavi MadhirajuMarch 8, 2024